MedTech Acquisition Corporation
MTAC · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.01 | 0.34 | 0.01 | -0.32 |
| FCF Yield | -0.80% | -1.94% | -1.62% | -11.38% |
| EV / EBITDA | 3,065.71 | -47.46 | -42.56 | -9.77 |
| Quality | ||||
| ROIC | -35.10% | -22.83% | -43.12% | -50.02% |
| Gross Margin | 83.52% | 83.93% | 83.69% | 86.06% |
| Cash Conversion Ratio | 0.34 | 0.88 | 0.43 | -21.59 |
| Growth | ||||
| Revenue 3-Year CAGR | 3,944,490.15% | 3,851,998.70% | 3,763,518.63% | 3,534,095.43% |
| Free Cash Flow Growth | 45.69% | -37.58% | 86.38% | -250.08% |
| Safety | ||||
| Net Debt / EBITDA | 70.17 | 3.42 | 1.58 | 0.00 |
| Interest Coverage | -6.17 | -5.15 | -6.06 | 10.53 |
| Efficiency | ||||
| Inventory Turnover | 0.58 | 0.47 | 0.36 | 0.00 |
| Cash Conversion Cycle | 193.60 | 234.85 | 304.09 | 0.00 |